Larotrectinib monotherapy (NAVIGATE / SCOUT) — NTRK fusion+ solid tumors (tumor-agnostic, incl. NSCLC)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-LAROTRECTINIB`

ID	`REG-LAROTRECTINIB-PANTUMOR`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-NAVIGATE-DRILON-2018` `SRC-NCCN-NSCLC-2025`

Notes

Pooled NAVIGATE / SCOUT / phase-1: ORR 75% (IRC) across 17 tumor types incl. NSCLC subset. Tumor-agnostic FDA approval 2018. NTRK fusion frequency in NSCLC ~0.2% — RNA-NGS panel testing required to identify. Best tolerated TRK inhibitor; entrectinib alternative (broader spectrum incl. ROS1 / ALK but more CNS-AE); repotrectinib next-gen for resistance mutations (G595R / G667C).

Used By

Indication

IND-NSCLC-2L-NTRK-LAROTRECTINIB - IND-NSCLC-2L-NTRK-LAROTRECTINIB
IND-NSCLC-NTRK-FUSION-1L-LAROTRECTINIB - IND-NSCLC-NTRK-FUSION-1L-LAROTRECTINIB